[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642273":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":53,"collaborators":10,"id":56,"slug":10,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":75,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"standard maintenance cohort",null,"Patients who, after completing the 5-week standard induction period (Weeks 0, 1, 2, 3, 4), received 300 mg maintenance treatment with ≥90% of recorded injection intervals falling within every 4 weeks ± 7 days (21-35 days).",[13],"Drug: Standard Maintenance",{"label":15,"type":10,"description":16,"interventionNames":17},"non-standard maintenance cohort","Patients who, after completing the standard induction period, during the maintenance treatment phase, had either:\n\nat least 3 consecutive documented 300 mg maintenance injections with intervals all longer than 5 weeks (\\>35 days); or at least 3 consecutive documented 150 mg maintenance injections with intervals falling within every 4 weeks ± 7 days (21-35 days).",[18],"Drug: Non-standard Maintenance",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Standard Maintenance","5-week standard induction period (Weeks 0, 1, 2, 3, 4) followed by 300 mg maintenance treatment with ≥90% of recorded injection intervals falling within every 4 weeks ± 7 days (21-35 days).",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Non-standard Maintenance","5-week standard induction period (Weeks 0, 1, 2, 3, 4) followed by at least 3 consecutive documented 300 mg maintenance injections with intervals all longer than 5 weeks (\\>35 days); or followed by at least 3 consecutive documented 150 mg maintenance injections with intervals falling within every 4 weeks ± 7 days (21-35 days).",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Yue TAO, MD","CONTACT","+86 13851998148","taoyue18@126.com",[36],{"facility":37,"status":10,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School","Nanjing","Jiangsu","210008","China",{"type":43,"coordinates":44},"Point",[45,46],118.77778,32.06167,{"lat":46,"lon":45},[49,51],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":50},"taoyue@126.com",{"name":31,"role":52,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":52,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"taoyue","MD","100642273",false,"NCT07642544","Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis","Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis: A Single-Center Real-World Cross-Sectional Retrospective Study","Inclusion Criteria:\n\n* Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis.\n* Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period.\n* Achieved PASI 75 response at the end of the induction period.\n* Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments.\n* Complete electronic medical record data available for extraction.\n\nExclusion Criteria:\n\n* Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period.\n* Irregular maintenance treatment pattern, or substantial missing data.\n* Use of other targeted biologic agents or small molecule drugs during the maintenance period.\n* Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy.\n* Participation in other interventional clinical trials that may confound efficacy assessment.","ALL","18 Years",{"count":65,"type":66},120,"ESTIMATED","OBSERVATIONAL","To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.",[70,71],"Psoriasis","Psoriasis (PsO)",[73,74],"psoriasis","secukinumab","NOT_YET_RECRUITING","2026-06-09",{"date":78,"type":79},"2026-06-11","ACTUAL",{"date":81,"type":66},"2026-06-01",{"date":83,"type":66},"2027-03-01",{"name":5,"class":6},1]